3SBio (HK:1530) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
3SBio’s subsidiary, Shenyang Sunshine, has entered into a strategic agreement with Haihe Biopharma to exclusively commercialize Paclitaxel Oral Solution in Mainland China and Hong Kong. This collaboration involves Shenyang Sunshine making initial and milestone payments to RMX Biopharma, which will continue overseeing clinical trials and development. Investors are advised to remain cautious as the product’s successful commercialization is not guaranteed.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.